AbbVie's Etentamig Reduces Progression and Death Risk by 60% in Myeloma Phase 3 Trial
CERVINO Phase 3 Trial Meets Both Primary Endpoints
AbbVie (ABBV) announced that etentamig (ABBV-383) met both co-primary endpoints of overall response rate (ORR) and progression-free survival (PFS) in the global Phase 3 CERVINO trial involving 393 patients with relapsed or refractory multiple myeloma. The ORR in the etentamig group was 74.0%, significantly higher than 45.7% in the investigator-selected standard-of-care group. The PFS hazard ratio (HR) was 0.40, indicating a 60% reduction in the risk of progression or death. Both results had p-values below 0.0001, demonstrating strong statistical significance, and the PFS benefit was observed consistently across all predefined subgroups, supporting the consistency of the data for regulatory submissions.
Monthly Dosing as a Differentiator
Etentamig, which does not yet have a brand name, is a second-generation bispecific T-cell engager that simultaneously targets B-cell maturation antigen (BCMA) and CD3 on T cells. It is administered intravenously every four weeks following a single-step dose escalation. In a median follow-up of 11.4 months, the 12-month overall survival (OS) rate was 87.9% versus 72.0%, with an HR of 0.48, although it did not reach the pre-specified OS efficacy boundary, necessitating further follow-up. Cytokine release syndrome (CRS) occurred in 28.3% of patients, mostly Grade 1, with no Grade 3 or higher cases. Grade 3 or 4 infections were reported in 27.7% of patients, higher than the 19.2% in the control group. However, fatal infections were 1.5% versus 3.1%, and treatment discontinuation due to adverse events was 3.6% versus 9.6%, suggesting that etentamig's efficacy, combined with manageable safety, supports its potential for broader use in community hospitals and outpatient settings.
Competition with Existing Therapies and BCMA Agents
The control arm included combinations of carfilzomib-dexamethasone, elotuzumab-pomalidomide-dexamethasone, and selinexor-bortezomib-dexamethasone. Patients had a median of three prior lines of therapy, including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies. Direct competitors include Johnson & Johnson (JNJ)'s Tecvayli (teclistamab-cqyv), Pfizer (PFE)'s Elrexfio (elranatamab-bcmm), and Regeneron Pharmaceuticals (REGN)'s Lynozyfic (linvoseltamab-gcpt), all of which are BCMA×CD3 bispecific antibodies. These agents received accelerated FDA approval on October 25, 2022, August 14, 2023, and July 2, 2025, respectively. Etentamig is currently in Phase 3 development and has not yet undergone regulatory review or advisory committee evaluation by the FDA, EMA, or PMDA.
Regulatory Path and Commercial Implications
AbbVie plans to present full results at the International Myeloma Workshop on September 23–26, 2026. This trial is significant because it demonstrates PFS superiority in a randomized controlled trial, unlike earlier BCMA agents that relied on single-arm response rates. The global multiple myeloma market is projected to reach USD 29.24 billion in 2025 and USD 31.00 billion in 2026, with North America accounting for 58.28% in 2025. However, regulatory and commercial competitiveness will depend on mature OS data, infection management, IV administration convenience, and real-world comparisons with subcutaneously administered competitors already in the market. This announcement is based on internal pipeline clinical success and does not involve upfront, milestone, royalty, or equity terms.
From an investor perspective, the 74.0% ORR and 0.40 PFS HR in a randomized Phase 3 trial provide strong regulatory support for etentamig's potential entry into the USD 29.24 billion multiple myeloma market in 2025. In the short term, the duration of response, OS maturity, and detailed analysis of the 27.7% Grade 3/4 infection rate in the full data to be presented in September 2026 will influence AbbVie's (ABBV) commercialization probability. For clinicians, the single-step dose escalation and monthly dosing from the first cycle offer a clinical hypothesis for improved CRS management and broader access in community hospitals. For the industry, FDA-approved competitors Tecvayli, Elrexfio, and Lynozyfic, as well as CAR-T therapies like ciltacabtagene, are already established, making efficacy alone insufficient—administration route, infection rates, and treatment sequencing are emerging competitive factors. In the medium to long term, success in early-line combination Phase 2/3 trials could position etentamig to move beyond late-line monotherapy and become a core growth asset in AbbVie's hematology-oncology portfolio.